Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ridgeback Biotherapeutics
Biotech
Is molnupiravir a turkey? Merck posts drop in antiviral efficacy
Merck revealed the relative risk reduction fell from 50% to 30% in the final analysis of its phase 3 COVID-19 data, sending its stock sliding down.
Nick Paul Taylor
Nov 29, 2021 6:15am
EMA starts rolling review of Merck's COVID-19 antiviral
Oct 25, 2021 7:50am
Merck seeks FDA nod for COVID antiviral 10 days after data drop
Oct 11, 2021 7:45am
Merck's oral COVID-19 antiviral slashes hospitalizations
Oct 1, 2021 6:47am
Merck cans one COVID-19 drug, scraps a clinical trial of another
Apr 15, 2021 8:20am
Merck has better luck with 2nd COVID-19 drug attempt
Mar 8, 2021 7:10am
